Navigation Links
Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Date:3/27/2008

r. Optimised for extended serum half-life, PRS-050 exhibits comparable binding and functional in vitro activity to approved VEGF antagonists. Potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as anti-tumour activity, have already been demonstrated for PRS-050 in various well-validated in vivo preclinical studies.

As a next generation VEGF antagonist, PRS-050 exploits several favourable characteristics of Anticalins(R), including compact protein structure, high intrinsic stability, broad formulation flexibility and small molecular size with the potential to penetrate neovascularized tumour tissue more effectively. PRS-050 is currently being prepared for a Phase I study in patients with advanced malignancies.

Further information on Pieris AG is available at http://www.pieris-ag.com

Anticalin(R) and Duocalin(R) are registered trademarks of Pieris AG.

About OrbiMed Advisors, LLC

OrbiMed is a preeminent asset management firm focused on the global health sciences industry, with over $6 billion in assets under management across a family of venture capital funds, hedge funds and other investment vehicles. OrbiMed's investment advisory activities were founded in 1989 by Samuel D. Isaly, with a vision to invest across the spectrum of healthcare companies from small privately-held firms to large multinational companies.

OrbiMed's investment team includes over 20 experienced professionals with backgrounds in science, medicine, finance and law. OrbiMed's professionals work together in a collaborative, team-oriented approach. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. Where appropriate, particularly within its venture capital activities, OrbiMed supports its invested companies in achieving strategic, financial and operational objectives via participation at the Board of Di
'/>"/>

SOURCE Pieris AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
2. Moodys Raises Rating for Gerresheimer
3. SleepQuest Raises Awareness of Sleep Disorders
4. Arthrosurface Raises $4 Million of Preferred Equity Financing
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
8. Primera Biosystems Raises $21 Million in Series B Private Round
9. Cellectar, Inc. Raises $13 Million in Private Offering
10. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... PA (PRWEB) October 17, 2014 ... being called upon by health facilities around the ... patients are being treated. Among the many places ... includes Texas Health Presbyterian Hospital Dallas and at ... The state-of-the-art vapor-producing robots have been utilized to ...
(Date:10/17/2014)... The global SWIR market report defines and ... of revenue. This market is valued at $60.1 million ... by 2019, at a CAGR of 10.2% from 2014 ... global SWIR market report, to get an idea of ... of the segmentation of the market, and is supported ...
(Date:10/17/2014)... The North American Knowledge-based/Evidence-based Clinical ... segments the market in North America with analysis ... in North America is expected to reach around ... of 8.1% from 2013 to 2018. , Browse ... clinical decision support system (CDSS) market, to get ...
(Date:10/17/2014)... The Middle East and Africa Location Based Services (LBS) ... Middle East and Africa with analysis and forecast of revenue. ... 2014 to $3,403.1 million by 2019, at a CAGR of ... of the Middle East and Africa Location Based Services (LBS) ... provided. It also provides a glimpse of the market segmentation, ...
Breaking Biology Technology:Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 2The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 4The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 5The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 2The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 3The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 4
... CITY, Dec. 4 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... take part in a panel discussion titled, "Replacing The ... RBC Capital Markets 2008 Healthcare Conference on Wednesday, December ...
... and secondhand smoke, an estimated ten percent of pregnant women ... baby to harmful cigarette byproducts from mothers who smoke affects ... health care burden. , Now, in the first study of ... assessment of newborns, umbilical cord blood to better understand the ...
... Dec. 3 CeloNova BioSciences, Inc., announced,today that ... is commercializing the,CATANIA(TM) Coronary Stent System with NanoThin ... any stent thrombosis in clinical studies. It is ... now some Middle,Eastern countries with aggressive world-wide expansion ...
Cached Biology Technology:Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... method could enable scientists to generate snapshots of dozens of ... team from the Wyss Institute of Biologically Inspired Engineering at ... Such images could shed light on complex cellular pathways ... its prognosis, or monitor the effectiveness of therapies at a ...
... of East Anglia is launching a project to predict how ... sea ice chamber and using state-of-the-art computer models. The ... ocean, sea ice, snow and the atmosphere in polar regions. ... the European Research Council (ERC). Lead researcher Prof Roland ...
... neurodevelopmental disorders, different parts of the brain don,t talk ... for the first time, a way in which this ... published online today in Nature Neuroscience , scientists ... Italy, and collaborators at the Istituto Italiano di Tecnologia ...
Cached Biology News:Capturing ultrasharp images of multiple cell components at once 2Capturing ultrasharp images of multiple cell components at once 3€2M EU funding for UEA project to understand Arctic ice melt 2Making your brain social 2
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
...
Biology Products: